Monte Rosa Therapeutics develops molecular glue degrader medicines.
1 report, 1 independent
Updated Jul 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Monte Rosa Therapeutics develops molecular glue degrader medicines.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Monte Rosa Therapeutics published key research insights in the journal Science on July 4, 2025. John Castle served as the Chief Data Officer during this publication.Sub-event
Monte Rosa Therapeutics is developing molecular glue degrader medicines.1 source
Keep exploring
The entities involved
-
Monte Rosa Therapeutics
biotechnology company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireMonte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases MRT-8102 Phase 1 study